Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing-Reference-Cited by-同舟云学术

Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing

Published:2022-09 Issue:9 Volume:3 Page:100381
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Kim So Yeon,Yin Jun,Bohlman Stephen,Walker Phillip,Dacic Sanja,Kim Chul,Khan Hina,Liu Stephen V.,Ma Patrick C.,Nagasaka Misako,Reckamp Karen L.,Abraham Jim,Uprety Dipesh,Wang Feng,Xiu Joanne,Zhang Jian,Cheng Haiying,Halmos Balazs

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference48 articles.

1. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer;Ma;Cancer Res,2005

2. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors;Frampton;Cancer Discov,2015

3. Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations;Schrock;J Thorac Oncol,2016

4. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-met overexpression;Awad;J Clin Oncol,2016

5. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities;Zhang;Mol Cancer,2018

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer;CLIN LUNG CANCER;2024

2. Novel molecular subtypes of METex14 non-small cell lung cancer with distinct biological and clinical significance;npj Precision Oncology;2024-07-26

3. Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors;Cancer Discovery;2024-04-02

4. MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutations;Translational Lung Cancer Research;2024-04

5. Real-world analysis of MET exon 14 mutations in non-small cell lung cancer: a retrospective study from two Swedish hospitals;Acta Oncologica;2023-10-28